Clonidine in Patients Undergoing Noncardiac Surgery
PJ Devereaux, DI Sessler, K Leslie, A Kurz, M Mrkobrada, P Alonso-Coello, JC Villar, A Sigamani, BM Biccard, CS Meyhoff, JL Parlow, G Guyatt, A Robinson, AX Garg, RN Rodseth, F Botto, G Lurati Buse, D Xavier, MTV Chan, M Tiboni Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014
BACKGROUND: Marked activation of the sympathetic nervous system occurs during and after noncardiac surgery. Low-dose clonidine, which blunts central sympathetic outflow, may prevent perioperative myocardial infarction and death without inducing hemodynamic instability. METHODS: We performed a blinded, randomized trial with a 2-by-2 factorial design to allow separate evaluation of low-dose clonidine versus placebo and low-dose aspirin versus placebo in patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac surgery. A total of 10,010 patients at 135 centers in 23 countries were enrolled. For the comparison of clonidine with placebo, patients were randomly assigne..View full abstract
Awarded by NATIONAL CANCER INSTITUTE
Supported by grants from the Canadian Institutes of Health Research, the Commonwealth Government of Australia's National Health and Medical Research Council, the Spanish Ministry of Health and Social Policy, and Boehringer Ingelheim. Bayer Pharma provided the aspirin study drug, and Boehringer Ingelheim the clonidine study drug.